# Meningococcal (A,C,W,Y) Vaccine

## Vaccine Description
- Brands: Menveo® and MenQuadfi®
- Inactivated, bacterial polysaccharide conjugate (MCV4)
- See package insert

## Dose & Route
- Dose: 0.5 mL
- Route: IM (Menveo®, MenQuadfi®) (Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy)
- See package insert

## Indications
- Routine vaccination against meningococcal disease is not recommended for children aged 2 months through 10 years of age.
- All children at age 11 to 12 years and unvaccinated adolescents at subsequent visit
- College freshmen living in dormitories
- Children 2 months and older who:
  - Have functional or anatomic asplenia, including sickle cell disease
  - Have certain immune system disorders (complement component deficiency)
  - Are traveling to or living in an endemic area
  - Have been exposed to meningitis during an outbreak
  - Have HIV
  - Are taking a complement inhibitor (e.g., Solaris)
- Menveo® is licensed for use in ages 2 months - 55 years of age; MenQuadfi® is licensed for ages 2 years and older

## Administration Schedule

<table>
<thead>
<tr>
<th>Age</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>INCREASED RISK</td>
<td>Primary vaccination: Menveo: If first dose at age:</td>
</tr>
<tr>
<td>2-23 mos of age</td>
<td>• 2 mos: 4 doses at 2, 4, 6, and 12 mos</td>
</tr>
<tr>
<td>(complement deficiency; asplenia; outbreak; HIV; travel)</td>
<td>• 3–6 mos: 8-week intervals until ≥ 7 months. One additional dose is given ≥7 months followed by 1 dose at least 12 weeks later and after the 1st birthday</td>
</tr>
<tr>
<td></td>
<td>• 7–23 mos: 2 doses (second dose ≥12 wks after the first dose and after the 1st birthday)</td>
</tr>
<tr>
<td>NO RISK</td>
<td>Give dose #1 of 2-dose MCV4 series. Dose #2 will be due at age 16 years.</td>
</tr>
<tr>
<td>11-18 yrs of age</td>
<td>For 1st yr college student (19 - 21 yrs in dorm): 1 dose MCV4 if none prior, or 1 dose (#2) if single dose given before age 16.</td>
</tr>
</tbody>
</table>

Continued on Next Page
# Meningococcal (A,C,W,Y) Vaccine

(Continued)

<table>
<thead>
<tr>
<th>Administration Schedule (continued)</th>
<th>TRAVEL RISK 2-18 yrs of age (Travel to endemic area or outbreak)</th>
<th>If unimmunized: 1 dose of MCV4 with booster every 5 years if travel risk persists</th>
</tr>
</thead>
</table>
| See package insert for vaccine-specific schedule | HEALTH RISK 2-18 yrs of age (complement deficiency; asplenia, HIV) | Primary: Menveo or MenQuadfi  
- 2 doses ≥8 wks apart  
- Boosters (if person remains at increased risk)  
- Aged <7 yrs: Single dose at 3 yrs after primary vaccination and every 5 yrs thereafter  
- Aged ≥7 yrs: Single dose at 5 yrs after primary vaccination and every 5 yrs thereafter |

| Contraindications | • Serious allergic reaction to prior dose or vaccine component  
• Moderate or severe acute illness  
• Children younger than 2 months of age (Menveo®) or 2 years of age (MenQuadfi®)  
• Menveo: severe allergic reaction to any diphtheria toxoid or CRM197 containing vaccine  
• MenQuadfi: severe allergic reaction to a tetanus toxoid-containing vaccine |

| Special Considerations | • Menveo® and Menquadfi® have not been widely studied in pregnant and lactating women and should be given only if clearly indicated.  
• **Penbraya (MenABCWY) is licensed as a 2-dose series given 6 months apart, for individuals aged 10-25 years. Pfizer’s MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit for:  
  - Healthy individuals age 16 through 23 years (routine schedule) when shared clinical decision-making (SCDM) favors administration of MenB vaccination (requires order from privileged provider).  
  - Individuals age 10 years and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for both vaccines  
  - The MenB component of Penbraya is the MenB vaccine Trumenba. As Trumenba and Bexsero are not interchangeable, a primary series and any future MenB booster doses must be of the same brand.  
  - See Storage and Handling Section |

VIS: [http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening.html](http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening.html)  
Standing orders: [www.health.mil/standingorders](http://www.health.mil/standingorders)  
Pregnancy registry for Menactra®: 1-800-822-2463  
Pregnancy registry for Menveo®: 1-877-413-4759; also notify DHA-IHD  
Additional education may be found at [www.health.mil/meningococcal](http://www.health.mil/meningococcal)